Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 1/20 | 0.41 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | CLCN2 | P51788 | 1/20 | 0.38 |
| ▸ | LCK | P06239 | 1/20 | 0.37 |
| ▸ | FYN | P06241 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | XDH | P47989 | 1/20 | 0.35 |
| ▸ | FABP3 | P05413 | 1/20 | 0.35 |
| ▸ | FABP4 | P15090 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31425472 | 1.00 | P2RX3 (0.41) | P2RX3P2RX2EGFRTSHRHSD17B10 | |
| SCHEMBL1019195 | 0.88 | HSP90AA1 (0.40) | P2RX3P2RX2EGFRTSHRHSD17B10 | |
| SCHEMBL1019840 | 0.88 | EGFR (0.39) | P2RX3P2RX2EGFRTSHRHSD17B10 | |
| SCHEMBL14930787 | 0.88 | CYP3A4 (0.51) | EGFRTSHRLMNACYP3A4CYP1A2 | |
| SCHEMBL1018574 | 0.86 | CHEK1 (0.41) | EGFRTSHRMAPTLMNAKDM4E | |
| SCHEMBL14381333 | 0.86 | P2RX3 (0.43) | P2RX3P2RX2EGFRTSHRLMNA | |
| SCHEMBL14380932 | 0.84 | LMNA (0.34) | EGFRTSHRHSD17B10MAPTHPGD | |
| SCHEMBL4999364 | 0.84 | CTSD (0.39) | EGFRTSHRMAPTPOLBLMNA | |
| SCHEMBL4567029 | 0.81 | PTPN11 (0.50) | TSHRHSD17B10ALDH1A1RXRA | |
| SCHEMBL12726581 | 0.79 | TDP1 (0.38) | TSHRHSD17B10MAPTHPGDLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3568128-B1 | HSP90B N-TERMINAL ISOFORM-SELECTIVE INHIBITORS | UNIV KANSAS (US) | 2022-07-06 | — | — | EP | disclosed |
| US-10927076-B2 | HSP90B N-terminal isoform-selective inhibitors | UNIVERSITY OF KANSAS (US) | 2021-02-23 | — | — | US | disclosed |
| EP-3568128-A1 | HSP90B N-TERMINAL ISOFORM-SELECTIVE INHIBITORS | The University of Kansas (US) | 2019-11-20 | — | — | EP | disclosed |
| US-20190337894-A1 | HSP90B N-TERMINAL ISOFORM-SELECTIVE INHIBITORS | UNIVERSITY OF KANSAS | 2019-11-07 | — | — | US | disclosed |
| WO-2018132769-A1 | HSP90B N-TERMINAL ISOFORM-SELECTIVE INHIBITORS | UNIVERSITY OF KANSAS (US) | 2018-07-19 | — | — | WO | disclosed |
| EP-2271618-B1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LTD (GB) | 2014-05-21 | — | — | EP | disclosed |
| EP-2271618-B1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LTD (GB) | 2014-05-21 | — | — | EP | disclosed |
| US-8664218-B2 | Pharmaceutical compounds | ASTEX THERAPEUTICS LTD. (GB) | 2014-03-04 | — | — | US | disclosed |
| US-8664218-B2 | Pharmaceutical compounds | ASTEX THERAPEUTICS LTD. (GB) | 2014-03-04 | — | — | US | disclosed |
| US-8664218-B2 | Pharmaceutical compounds | ASTEX THERAPEUTICS LTD. (GB) | 2014-03-04 | — | — | US | disclosed |
| US-20110098290-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2011-04-28 | — | — | US | disclosed |
| US-20110098290-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2011-04-28 | — | — | US | disclosed |
| US-20110098290-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2011-04-28 | — | — | US | disclosed |
| EP-2271618-A1 | PHARMACEUTICAL COMPOUNDS | Astex Therapeutics Limited (GB) | 2011-01-12 | — | — | EP | disclosed |
| WO-2009125230-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2009-10-15 | — | — | WO | disclosed |
| WO-2009125230-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2009-10-15 | — | — | WO | disclosed |
| US-20080269218-A1 | Novel Hsp90 Inhibitor | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2008-10-30 | — | — | US | disclosed |
| US-20080269218-A1 | Novel Hsp90 Inhibitor | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2008-10-30 | — | — | US | disclosed |
| US-20080269218-A1 | Novel Hsp90 Inhibitor | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2008-10-30 | — | — | US | disclosed |
| EP-1857446-A1 | NOVEL HSP90 INHIBITOR | Nippon Kayaku Kabushiki Kaisha (JP) | 2007-11-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190337894-A1 | HSP90B N-TERMINAL ISOFORM-SELECTIVE INHIBITORS | HSP90AB1, HSP90AB2P, HSP90B1 | P2RX3 4614/4885P2RX2 4622/4885EGFR 946/4885 |
| US-10927076-B2 | HSP90B N-terminal isoform-selective inhibitors | HSP90AB1, HSP90AB2P, HSP90B1 | P2RX3 4614/4885P2RX2 4622/4885EGFR 946/4885 |
| US-20110098290-A1 | PHARMACEUTICAL COMPOUNDS | NR3C2, NR5A2, NR0B1 | P2RX3 1943/4885P2RX2 2479/4885EGFR 933/4885 |
| US-20080269218-A1 | Novel Hsp90 Inhibitor | HSP90AB1, HSP90AB2P, HSP90B1 | P2RX3 4133/4885P2RX2 4287/4885EGFR 3603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.